ARTICLE | Company News
Expression Genetics, U.S. Food and Drug Administration cancer news
May 7, 2007 7:00 AM UTC
Expression Genetics received a $1.1 million Orphan Products Development Grant from FDA to aid in development of EGEN-001 to treat advanced-stage recurrent ovarian cancer. The interleukin-12 (IL-12) ...